Pfizer’s Talzenna Takes On Top Dog Lynparza In Prostate Cancer

 
• By Alaric DeArment

Top-line Phase III results for Talzenna/Xtandi showed improved PFS in mCRPC patients regardless of HRR mutation status, where AstraZeneca/Merck have developed fellow PARP inhibitor Lynparza.

Pfizer announced positive topline results from the TALAPRO-2 trial in mCRPC • Source: Shutterstock

More from Clinical Trials

More from R&D